CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 178.81 AUD -1.55% Market Closed
Market Cap: 86.7B AUD
Section:
 

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is hidden AUD. Compared to the current market price of 178.81 AUD, CSL Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.7
P/S
P/S
Price to Sales
3.7
vs History
96
vs Industry
60
Median 3Y
6.3
Median 5Y
7.9
Industry
7.9
Forward
3.6
More Details
19.3
P/E
P/E
Price to Earnings
19.3
vs History
96
vs Industry
6
Median 3Y
36
Median 5Y
37.9
Industry
24
Forward
16.9
More Details
16.2
P/OCF
P/OCF
Price to OCF
16.2
vs History
96
vs Industry
7
Median 3Y
32.5
Median 5Y
32.3
Industry
21.6
More Details
41.5
P/FCFE
P/FCFE
Price to FCFE
41.5
vs History
58
vs Industry
4
Median 3Y
54
Median 5Y
54.6
Industry
23.7
More Details
3
P/B
P/B
Price to Book Value
3
vs History
96
vs Industry
23
Median 3Y
5.2
Median 5Y
5.9
Industry
3.4
More Details
4.3
EV/S
EV/S
Enterprise Value to Sales
4.3
vs History
96
vs Industry
47
Median 3Y
7
Median 5Y
7.7
Industry
8.3
Forward
4.1
More Details
8.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.2
vs History
96
vs Industry
36
Median 3Y
13.5
Median 5Y
14.3
Industry
10.3
More Details
13
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13
vs History
96
vs Industry
8
Median 3Y
21.9
Median 5Y
23.1
Industry
6.7
Forward
11.9
More Details
16.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.2
vs History
96
vs Industry
7
Median 3Y
27.2
Median 5Y
28.4
Industry
7.2
Forward
13.8
More Details
18.7
EV/OCF
EV/OCF
Enterprise Value to OCF
18.7
vs History
96
vs Industry
5
Median 3Y
35.8
Median 5Y
33.1
Industry
8.2
More Details
25.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
25.9
vs History
96
vs Industry
3
Median 3Y
71.2
Median 5Y
66.8
Industry
6.7
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
96
vs Industry
43
Median 3Y
3
Median 5Y
3.3
Industry
5.7
More Details

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
86.6B AUD 3.7 19.3 13 16.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 924 975 -161 240.4 -195 797.2 -193 563
US
Abbvie Inc
NYSE:ABBV
395.1B USD 6.6 168.4 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
171.7B USD 4.8 24.5 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
153.3B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 9.6 30.7 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 076.6 -529.9 -577 -561.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.5B USD 5.4 17 16.1 18.2
NL
argenx SE
XBRU:ARGX
46.7B EUR 15.1 35.6 61.6 63.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 230.6 161.8 196.2
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.3 -66.1 -59.7
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 084 285.4
3.7
5%
0.7
FR
Pharnext SCA
OTC:PNEXF
33 924 975
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 076.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
US
S
Seagen Inc
F:SGT
20
30%
0.7
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 193.1
19.3
11%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 240.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.5
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
NL
argenx SE
XBRU:ARGX
35.6
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 230.6
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 40.2
13
8%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 797.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
NL
argenx SE
XBRU:ARGX
61.6
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.8
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 46.4
16.2
11%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 563 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
NL
argenx SE
XBRU:ARGX
63.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.2
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A

See Also

Summary
CSL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CSL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CSL stock valuation using valuation multiples.
Wall Street Estimates
CSL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CSL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.